Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma

Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation

J Allergy Clin Immunol.

Jevnikar Z, Östling J, Ax E, Calvén J, Thörn K, Israelsson E, Öberg L, Singhania A, Lau LCK, Wilson SJ, Ward JA, Chauhan A, Sousa AR, De Meulder B, Loza MJ, Baribaud F, Sterk PJ, Chung KF, Sun K, Guo Y, Adcock IM, Payne D, Dahlen B, Chanez P, Shaw DE, Krug N, Hohlfeld JM, Sandström T, Djukanovic R, James A, Hinks TSC, Howarth PH, Vaarala O, van Geest M, Olsson HK; U-BIOPRED study group

doi: 10.1016/j.jaci.2018.05.026.

RECOMMENDED

Asthma

"T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin

Eur Respir J.

Pavlidis S, Takahashi K, Ng Kee Kwong F, Xie J, Hoda U, Sun K, Elyasigomari V, Agapow P, Loza M, Baribaud F, Chanez P, Fowler SJ, Shaw DE, Fleming LJ, Howarth PH, Sousa AR, Corfield J, Auffray C, De Meulder B, Knowles R, Sterk PJ, Guo Y, Adcock IM, Djukanovic R, Fan Chung K, on behalf of the U-BIOPRED Study Group

doi: 10.1183/13993003.

Asthma

Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials

Lancet Respir Med.

Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S, Maitra S, Lawrence D, Brockhaus F, Lehmann T, Brindicci C, Knorr B, Bleecker ER

doi: 10.1016/S2213-2600(20)30412-4.

RECOMMENDED

Asthma

Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma

Clin Pharmacol Ther.

Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L

doi: 10.1002/cpt.

RECOMMENDED

Asthma

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

J Allergy Clin Immunol.

Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB

doi: 10.1016/j.jaci.2018.08.031.

RECOMMENDED

Asthma

Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function

Respir Med.

Mansur AH, Srivastava S, Sahal A

doi: 10.1016/j.rmed.2018.08.005.

Asthma

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

Drug Des Devel Ther.

Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G

doi: 10.2147/

Asthma

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

Lancet Respir Med.

Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A

doi: 10.1016/

COMMENTED

Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data

J Asthma.

Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B

doi: 10.1080/

Related content

Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation

"T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin

Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials

Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data